{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:45:23Z","timestamp":1785278723012,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.lpm.2021.104085","type":"journal-article","created":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T11:00:29Z","timestamp":1635591629000},"page":"104085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Complications of lipodystrophy syndromes"],"prefix":"10.1016","volume":"50","author":[{"given":"Gulcin","family":"Akinci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1112-7640","authenticated-orcid":false,"given":"Merve","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8634-4845","authenticated-orcid":false,"given":"Baris","family":"Akinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lpm.2021.104085_bib0001","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1210\/jc.2004-0395","article-title":"Adipose tissue as an endocrine organ","volume":"89","author":"Kershaw","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.lpm.2021.104085_bib0002","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s42255-019-0095-y","article-title":"Leptin and the endocrine control of energy balance","volume":"1","author":"Friedman","year":"2019","journal-title":"Nat Metab"},{"issue":"5","key":"10.1016\/j.lpm.2021.104085_bib0003","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1210\/jcem.87.5.8624","article-title":"Serum adiponectin and leptin levels in patients with lipodystrophies","volume":"87","author":"Haque","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.lpm.2021.104085_bib0004","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1677\/JOE-10-0272","article-title":"Lipodystrophy: metabolic insights from a rare disorder","volume":"207","author":"Huang-Doran","year":"2010","journal-title":"J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104085_bib0005","series-title":"Endotext","article-title":"Lipodystrophy Syndromes: presentation and Treatment","author":"Akinci","year":"2000"},{"issue":"7","key":"10.1016\/j.lpm.2021.104085_bib0006","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/dom.12606","article-title":"One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes","volume":"18","author":"Vatier","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.lpm.2021.104085_bib0007","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/dom.12796","article-title":"First metreleptin treatment for generalized lipodystrophy in Turkey","volume":"19","author":"Simsir","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.lpm.2021.104085_bib0008","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1210\/jc.2018-02730","article-title":"Comorbidities and survival in patients with lipodystrophy: an international chart review study","volume":"104","author":"Akinci","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.lpm.2021.104085_bib0009","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1210\/jc.2016-1005","article-title":"Natural history of congenital generalized lipodystrophy: a nationwide study from Turkey","volume":"101","author":"Akinci","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104085_bib0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.metabol.2017.04.010","article-title":"Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy","volume":"72","author":"Akinci","year":"2017","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.lpm.2021.104085_bib0011","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00005792-200303000-00007","article-title":"Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature","volume":"82","author":"Misra","year":"2003","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.lpm.2021.104085_bib0012","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","article-title":"Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature","volume":"83","author":"Misra","year":"2004","journal-title":"Medicine"},{"key":"10.1016\/j.lpm.2021.104085_bib0013","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.molimm.2019.05.011","article-title":"An overview of lipodystrophy and the role of the complement system","volume":"112","author":"Corvillo","year":"2019","journal-title":"Mol Immunol"},{"issue":"12","key":"10.1016\/j.lpm.2021.104085_bib0014","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.lpm.2021.104085_bib0015","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.metabol.2015.06.004","article-title":"Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities","volume":"64","author":"Akinci","year":"2015","journal-title":"Metabolism"},{"issue":"1\u20132","key":"10.1016\/j.lpm.2021.104085_bib0016","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/07435800.2018.1513029","article-title":"A subset of patients with acquired partial lipodystrophy developing severe metabolic abnormalities","volume":"44","author":"Ozgen Saydam","year":"2019","journal-title":"Endocr Res"},{"issue":"12","key":"10.1016\/j.lpm.2021.104085_bib0017","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.lpm.2021.104085_bib0018","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/17446651.2020.1735360","article-title":"Diagnostic strategies and clinical management of lipodystrophy","volume":"15","author":"Foss-Freitas","year":"2020","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.lpm.2021.104085_bib0019","doi-asserted-by":"crossref","DOI":"10.1007\/s11892-018-1099-9","article-title":"Phenotypic and genetic characteristics of lipodystrophy: pathophysiology, metabolic abnormalities, and comorbidities","volume":"18","author":"Akinci","year":"2018","journal-title":"Curr Diabetes Rep"},{"issue":"10","key":"10.1016\/j.lpm.2021.104085_bib0020","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.2337\/dc20-1655","article-title":"Diabetic foot ulcers: a neglected complication of lipodystrophy","volume":"43","author":"Saydam","year":"2020","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.lpm.2021.104085_bib0021","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.tem.2011.04.007","article-title":"Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance","volume":"22","author":"Choi","year":"2011","journal-title":"Trends Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.lpm.2021.104085_bib0022","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1467-789X.2011.00900.x","article-title":"Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management","volume":"12","author":"Van de Woestijne","year":"2011","journal-title":"Obes Rev"},{"issue":"5","key":"10.1016\/j.lpm.2021.104085_bib0023","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S1262-3636(07)70061-7","article-title":"Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease","volume":"29","author":"Diraison","year":"2003","journal-title":"Diabetes Metab"},{"issue":"4A","key":"10.1016\/j.lpm.2021.104085_bib0024","doi-asserted-by":"crossref","first-page":"7B","DOI":"10.1016\/S0002-9149(98)00031-9","article-title":"Hypertriglyceridemia as a cardiovascular risk factor","volume":"81","author":"Austin","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.lpm.2021.104085_bib0025","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.metabol.2019.05.001","article-title":"Fatty liver in lipodystrophy: a review with a focus on therapeutic perspectives of adiponectin and\/or leptin replacement","volume":"96","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.lpm.2021.104085_bib0026","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1194\/jlr.P056002","article-title":"Biomarkers of NAFLD progression: a lipidomics approach to an epidemic","volume":"56","author":"Gorden","year":"2015","journal-title":"J Lipid Res"},{"issue":"5","key":"10.1016\/j.lpm.2021.104085_bib0027","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.lpm.2021.104085_bib0028","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/TP.0000000000002480","article-title":"Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH","volume":"103","author":"Pierantonelli","year":"2019","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.lpm.2021.104085_bib0029","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40618-018-0887-z","article-title":"Diagnosis and treatment of lipodystrophy: a step-by-step approach","volume":"42","author":"Araujo-Vilar","year":"2019","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"10.1016\/j.lpm.2021.104085_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4274\/jcrpe.galenos.2019.2019.0124","article-title":"Current diagnosis, treatment and clinical challenges in the management of lipodystrophy syndromes in children and young people","volume":"12","author":"Ozen","year":"2020","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"14","key":"10.1016\/j.lpm.2021.104085_bib0031","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137180","article-title":"Leptin decreases de novo lipogenesis in patients with lipodystrophy","volume":"5","author":"Baykal","year":"2020","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.lpm.2021.104085_bib0032","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1210\/er.2012-1053","article-title":"Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals","volume":"34","author":"Moon","year":"2013","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.lpm.2021.104085_bib0033","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.metabol.2014.08.004","article-title":"Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism","volume":"64","author":"Park","year":"2015","journal-title":"Metabolism"},{"issue":"11","key":"10.1016\/j.lpm.2021.104085_bib0034","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1210\/en.2008-0498","article-title":"Leptin regulates peripheral lipid metabolism primarily through central effects on food intake","volume":"149","author":"Prieur","year":"2008","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.lpm.2021.104085_bib0035","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.molmet.2017.04.011","article-title":"The glucoregulatory actions of leptin","volume":"6","author":"D'souza","year":"2017","journal-title":"Mol Metab"},{"issue":"7","key":"10.1016\/j.lpm.2021.104085_bib0036","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1210\/jc.2003-032140","article-title":"Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy","volume":"89","author":"Javor","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.lpm.2021.104085_bib0037","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/cen.13732","article-title":"Renal complications of lipodystrophy: a closer look at the natural history of kidney disease","volume":"89","author":"Akinci","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"2","key":"10.1016\/j.lpm.2021.104085_bib0038","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1464-5491.2009.02909.x","article-title":"Post-mortem findings in Dunnigan-type familial partial lipodystrophy","volume":"27","author":"Ludtke","year":"2010","journal-title":"Diabet Med"},{"issue":"1\u20132","key":"10.1016\/j.lpm.2021.104085_bib0039","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000354716","article-title":"Cosegregation of focal segmental glomerulosclerosis in a family with familial partial lipodystrophy due to a mutation in LMNA","volume":"124","author":"Thong","year":"2013","journal-title":"Nephron Clin Pract"},{"issue":"2","key":"10.1016\/j.lpm.2021.104085_bib0040","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pathol.2018.11.004","article-title":"Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease","volume":"51","author":"Hussain","year":"2019","journal-title":"Pathology"},{"issue":"4","key":"10.1016\/j.lpm.2021.104085_bib0041","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MD.0b013e3181e9442f","article-title":"Gorden P: cardiomyopathy in congenital and acquired generalized lipodystrophy: a clinical assessment","volume":"89","author":"Lupsa","year":"2010","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.lpm.2021.104085_bib0042","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/cen.14426","article-title":"Cardiac phenotype in familial partial lipodystrophy","volume":"94","author":"Eldin","year":"2021","journal-title":"Clin Endocrinol"},{"issue":"11","key":"10.1016\/j.lpm.2021.104085_bib0043","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1210\/jc.2003-031658","article-title":"Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities","volume":"89","author":"Vantyghem","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"6\u20137","key":"10.1016\/j.lpm.2021.104085_bib0044","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejmg.2016.05.001","article-title":"Spectrum of clinical manifestations in two young Turkish patients with congenital generalized lipodystrophy type 4","volume":"59","author":"Akinci","year":"2016","journal-title":"Eur J Med Genet"},{"issue":"3","key":"10.1016\/j.lpm.2021.104085_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000874","article-title":"Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations","volume":"6","author":"Rajab","year":"2010","journal-title":"PLoS Genet"},{"issue":"4","key":"10.1016\/j.lpm.2021.104085_bib0046","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.diabet.2018.09.006","article-title":"Cardiometabolic assessment of lamin A\/C gene mutation carriers: a phenotype-genotype correlation","volume":"45","author":"Kwapich","year":"2019","journal-title":"Diabetes Metab"},{"issue":"2","key":"10.1016\/j.lpm.2021.104085_bib0047","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/mus.23827","article-title":"Genetic and clinical characteristics of skeletal and cardiac muscle in patients with lamin A\/C gene mutations","volume":"48","author":"Carboni","year":"2013","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.lpm.2021.104085_bib0048","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1194\/jlr.R023754","article-title":"Seipin: from human disease to molecular mechanism","volume":"53","author":"Cartwright","year":"2012","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.lpm.2021.104085_bib0049","first-page":"1649","article-title":"A novel LIPE nonsense mutation found using exome sequencing in siblings with late-onset familial partial lipodystrophy","volume":"30","author":"Farhan","year":"2014","journal-title":"Can J Cardiol"},{"issue":"1","key":"10.1016\/j.lpm.2021.104085_bib0050","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ajmg.a.37880","article-title":"Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathy","volume":"173","author":"Zolotov","year":"2017","journal-title":"Am J Med Genet A"},{"issue":"1","key":"10.1016\/j.lpm.2021.104085_bib0051","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1530\/EJE-20-1013","article-title":"LIPE-related lipodystrophic syndrome: clinical features and disease modeling using adipose stem cells","volume":"184","author":"Sollier","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104085_bib0052","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.23813","article-title":"Human biallelic MFN2 mutations induce mitochondrial dysfunction, upper body adipose hyperplasia, and suppression of leptin expression","volume":"6","author":"Rocha","year":"2017","journal-title":"eLife"},{"issue":"10","key":"10.1016\/j.lpm.2021.104085_bib0053","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.nmd.2017.05.015","article-title":"Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: a multicenter study","volume":"27","author":"Akinci","year":"2017","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1016\/j.lpm.2021.104085_bib0054","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1210\/jc.2017-02078","article-title":"A novel generalized lipodystrophy-associated progeroid syndrome due to recurrent heterozygous LMNA p.T10I mutation","volume":"103","author":"Hussain","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.lpm.2021.104085_bib0055","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF00241817","article-title":"The skeleton in congenital, generalized lipodystrophy: evaluation using whole-body radiographic surveys, magnetic resonance imaging and technetium-99 m bone scintigraphy","volume":"21","author":"Fleckenstein","year":"1992","journal-title":"Skelet Radiol"},{"issue":"6","key":"10.1016\/j.lpm.2021.104085_bib0056","doi-asserted-by":"crossref","first-page":"428","DOI":"10.5152\/dir.2017.17019","article-title":"Determining residual adipose tissue characteristics with MRI in patients with various subtypes of lipodystrophy","volume":"23","author":"Altay","year":"2017","journal-title":"Diagn Interv Radiol"},{"issue":"6","key":"10.1016\/j.lpm.2021.104085_bib0057","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199052","article-title":"Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy","volume":"13","author":"Lima","year":"2018","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.lpm.2021.104085_bib0058","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/jc.2016-2271","article-title":"Clinical features and management of non-HIV-related lipodystrophy in children: a systematic review","volume":"102","author":"Gupta","year":"2017","journal-title":"J Clin Endocrinol Metab"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498221000245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498221000245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:08:59Z","timestamp":1760105339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498221000245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0755498221000245"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2021.104085","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complications of lipodystrophy syndromes","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2021.104085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104085"}}